Merck Advanced Technologies Ltd. (President/Representative Director: Juergen Koenig), the Korean affiliate of Merck KGaA of Germany, held a "Merck LC Insight 2011" seminar on Oct. 31 at the Imperial Palace Hotel, Seoul, Korea.
Since the 1990s, the Merck global LC seminar has been held annually in Germany, Japan, Korea and Taiwan. This seminar is being held by every two years and it is the 11th LC seminar.
During the seminar, Merck revealed the latest progress in 7 key areas; Liquid Crystal Materials, Reactive Mesogens, OLED Displays, Phosphors for LED Lighting, Flexible Displays, Structuring Solutions and Organic Electronics/OPV, that made by headquarters and Merck UK engineers and researchers.
Through all of applications for display, lighting and photovoltaic, Merck introduced enhanced features and competitiveness of each product focusing on long lifetime, high efficiency and energy saving with environment-friendly as well as new development status of Liquid Crystal which will remain Merck's main business in the next display field.
In this seminar, Merck took special time to share Merck's innovative technical skills and medium / long term product portfolio with invited key customers not only mature TFT LCD panel makers LGD, SEC, SMD and Hydis but also new business industry makers such as ShinHwa intertek, LG Chem and Dong-woo Fine-Chem etc.
From this seminar, Merck reinforced reorganization as a long-term leader focusing on core LC technology of chemical materials in Korea and contributor to the Korea display industry.
In Korea, Merck leads the industry with its continuous R&D and M&S activities. It was again given an opportunity to show its technology leadership to industry experts at the seminar following the IMID conference held in October. Merck is recognized as a long-term leader focusing on core LC technology of chemical materials in Korea and a major contributor to the Korean display industry.
About Merck Korea
Merck Ltd. Korea, registered in 1989, and Merck Advanced Technologies Ltd., established in 2002, are the Merck companies in Korea and operate in prescription and over-the-counter pharmaceuticals: performance chemicals such as liquid crystals and effect pigments; and life science products and analytics. In 1999, Merck Korea set up its Korean pharmaceutical operation. This was integrated with Serono Korea after Merck KGaA's acquisition of Serono S.A. in 2007. Merck has increased the number of clinical trials in Korea and has a strong relationship with R&D in Korea, not only in the medical area but also in the chemical field. In 2008 Merck KGaA decided to invest € 11 million in a new Advanced Technology Center (ATC) to improve Merck's R&D and manufacturing capacities in Korea by providing high quality products in the rapidly increasing display market, while continuing to support customers by allowing them to achieve business success through advanced technologies and close relationships in a rapidly changing display technology. This investment also reconfirms Merck's commitment and responsibility to contribute innovative solutions for the future success of the Korean display industry. The Korean ATC was inaugurated in May 2010. Merck KGaA completed its acquisition of Millipore Corporation, a leading Life Science company based in the USA, in 2010. The Merck Millipore division offers a comprehensive range of products, technologies and services for pharma and biotech companies, as well as for academia, to improve laboratory productivity and develop and optimize manufacturing processes.
